HMGB1 and mesothelioma: Interestingly, in line with our findings, it is reported by the literature that the combination therapy of oncolytic adenoviruses with chemotherapeutic drugs and ICIs resulted in the enhanced expression of calreticulin on the cancer cell surface and a higher release of both ATP and HMGB-1 markers in mesothelioma and melanoma therapies [50,80].